News & Events

BeiGene selects GE’s FlexFactory™ biomanufacturing platform for pilot cGMP production facility in China

BeiGene selects GE’s FlexFactory™ biomanufacturing platform for pilot cGMP production facility in China

Facility will manufacture biologics for clinical trials

CHALFONT ST. GILES, UK and BEIJING, CHINA – 16 December 2015 – GE Healthcare’s Life Sciences business and BeiGene, Ltd. today announced that BeiGene has selected GE’s FlexFactory™ biomanufacturing platform for its first current Good Manufacturing Practices (cGMP) biomanufacturing facility in Suzhou, China. Currently under construction, the facility is expected to be operational by 2017.

BeiGene is a clinical-stage biopharmaceutical company focused on discovering and developing innovative, molecularly-targeted and immuno-oncological drugs that address severe unmet medical needs in a variety of cancer indications. Announced in August 2015, the company’s new pilot-scale facility will manufacture monoclonal antibodies in its biologics pipeline for clinical trial use.

Predominantly based on single-use technologies, the integrated FlexFactory platform installed at the Suzhou facility will help Beigene to significantly reduce the build-up and commissioning time and help to increase the speed to global markets, including the United States, Europe and China.

John V. Oyler, Chief Executive Officer, BeiGene, said: “We’re excited to be working with GE in connection with our new pilot production facility as we seek to accelerate and expand our development programs. GE’s FlexFactory gives us the speed, flexibility and quality that allows us to continue to focus on developing global, potentially best-in-class drugs for various cancer treatments.”

Olivier Loeillot, General Manager, Commercial BioProcess Asia, GE Healthcare Life Sciences, said: “BeiGene is an outstanding exponent of the new wave of exciting biopharma companies coming out of China. Their need to accelerate the development pathway and then reach the market quickly, coupled with a desire to meet global regulatory standards, is something GE is well-placed to support. Not just with the exceptional scalability and applicability of the FlexFactory, but with all the accompanying support for validation, training, and service.”

About BeiGene

BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 190+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients. For more information, please visit our website at

About GE Healthcare

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at

Issued for and on behalf of GE Healthcare by Instinctif Partners.
For more information please contact:

back to news


Tim WatsonPartner